Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07154381 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 4, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).
Trial Details
NCT Number NCT07154381
Lead Sponsor University Hospital, Essen
Conditions
(from sponsor)		 Cardiac Amyloidosis
Related terms Amyloid Neuropathies, Familial
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov